Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):1125-9. doi: 10.1177/039463200902200430.
The aim of this study is to determine the effects of a combination treatment with etanercept and spa rehabilitation versus etanercept alone on function, disability and quality of life in a group of patients with active ankylosing spondylitis (AS). Sixty patients with AS underwent etanercept as suggested by ASAS/EULAR recommendations. As the clinical and laboratory conditions improved, 30 patients accepted the proposal of coupling the medical therapy with a 7-day rehabilitation program in a thermal baths centre; the remaining 30 subjects continued to take the biologic agent alone. The comparisons between the 2 groups were made after 3 and 6 months. The primary outcome was an improvement in BASFI. The secondary outcome was an improvement in the visual analogic scale of EuroQol (EQ-5Dvas). After 6 months a statistically significant improvement in BASFI (p < 0.05) and EQ-5DVAS (p < 0.05) scores was observed in both groups. The mean change in EQ-5DVAS value showed a statistically significant difference in favour of the combination therapy group versus the monotherapy group (22 vs 32, p < 0.05). A therapeutic regimen combining etanercept with an intensive rehabilitation program contributes to disability reduction and ameliorates quality of life for AS patients.
本研究旨在确定依那西普联合水疗康复治疗与依那西普单药治疗对活动期强直性脊柱炎（AS）患者功能、残疾和生活质量的影响。60 例 AS 患者按照 ASAS/EULAR 建议接受依那西普治疗。随着临床和实验室条件的改善，30 例患者接受了将药物治疗与 7 天温泉中心康复计划相结合的建议；其余 30 例患者继续单独使用生物制剂。在 3 个月和 6 个月后对两组进行了比较。主要结局是 BASFI 改善。次要结局是 EuroQol（EQ-5Dvas）视觉模拟量表的改善。6 个月后，两组 BASFI（p < 0.05）和 EQ-5DVAS（p < 0.05）评分均有统计学显著改善。EQ-5DVAS 值的平均变化显示联合治疗组与单药治疗组之间存在统计学显著差异（22 对 32，p < 0.05）。依那西普联合强化康复治疗方案有助于减轻残疾，改善 AS 患者的生活质量。
